Uric acid and xanthine oxidase in heart failure - Emerging data and therapeutic implications

International Journal of Cardiology

Volumn 213, Issue , 2016, Pages 15-19

  Doehner, Wolfram ^a,b   Jankowska, Ewa A ^c   Springer, Jochen ^d   Lainscak, Mitja ^e   Anker, Stefan D ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e University Clinic of Respiratory Diseases   (Slovenia)

Author keywords

Cachexia; Ischemic stroke; MCAO model; Muscle; Sarcopenia

Indexed keywords

ALLOPURINOL; BENZBROMARONE; FEBUXOSTAT; OXIPURINOL; OXYGEN RADICAL; PROBENECID; RECOMBINANT URATE OXIDASE; URIC ACID; XANTHINE OXIDASE; REACTIVE OXYGEN METABOLITE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HEART FAILURE; HUMAN; HYPERURICEMIA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; STABLE ANGINA PECTORIS; UPREGULATION; URIC ACID BLOOD LEVEL; ENZYMOLOGY; METABOLISM; PATHOLOGY;

HEART FAILURE; HUMANS; PROGNOSIS; REACTIVE OXYGEN SPECIES; RISK FACTORS; URIC ACID; XANTHINE OXIDASE;

EID: 84940069192     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.08.089     Document Type: Article

References (76)

1. W. Doehner, M. Frenneaux, and S.D. Anker Metabolic impairment in heart failure. The myocardial and systemic perspective J. Am. Coll. Cardiol. 64 2014 1388 1400
2. J. Farkas, S. von Haehling, K. Kalantar-Zadeh, J.E. Morley, S.D. Anker, and M. Lainscak Cachexia as a major public health problem: frequent, costly, and deadly J. Cachex. Sarcopenia Muscle 4 2013 173 178
3. D. Habedank, F.J. Meyer, R. Hetzer, S.D. Anker, and R. Ewert J Relation of respiratory muscle strength, cachexia and survival in severe chronic heart failure Cachex. Sarcopenia Muscle 4 2013 277 285
4. W. Doehner, M. Rauchhaus, V.G. Florea, and et al. Uric acid in cachectic and non-cachectic patients with chronic heart failure: relationship to leg vascular resistance Am. Heart J. 141 2001 792 799
5. F. Leyva, S.D. Anker, J.W. Swan, I.F. Godsland, C.S. Wingrove, T.P. Chua, J.C. Stevenson, and A.J. Coats Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure Eur. Heart J. 18 1997 858 865
6. F. Leyva, T.P. Chua, S.D. Anker, and et al. Uric acid in chronic heart failure: a measure of the anaerobic threshold Metabolism 47 1998 1156 1159
7. F. Leyva, C.S. Wingrove, I.F. Godsland, and et al. The glycolytic pathway to coronary heart disease: a hypothesis Metabolism 47 1998 657 662
8. U.E. Ekelund, R.W. Harrison, O. Shokek, R.N. Thakkar, R.S. Tunin, H. Senzaki, D.A. Kass, E. Marban, and J.M. Hare Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure Circ. Res. 85 1999 437 445
9. T.P. Cappola, D.A. Kass, G.S. Nelson, R.D. Berger, G.O. Rosas, Z.A. Kobeissi, E. Marban, and J.M. Hare Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy Circulation 104 2001 2407 2411
10. H.E. Cingolani, J.A. Plastino, E.M. Escudero, B. Mangal, J. Brown, and N.G. Pérez The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study J. Card. Fail. 12 2006 491 498
11. A.F. Cicero, M. Rosticci, A. Parini, C. Baronio, S. D'Addato, and C. Borghi Serum uric acid is inversely proportional to estimated stroke volume and cardiac output in a large sample of pharmacologically untreated subjects: data from the Brisighella Heart Study Intern. Emerg. Med. 9 2014 655 660
12. N. Engberding, S. Spiekermann, A. Schaefer, A. Heineke, A. Wiencke, M. Muller, M. Fuchs, D. Hilfiker-Kleiner, B. Hornig, H. Drexler, and U. Landmesser Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction Circulation 110 2004 2175 2179
13. C.A. Farquharson, R. Butler, A. Hill, J.J. Belch, and A.D. Struthers Allopurinol improves endothelial dysfunction in chronic heart failure Circulation 106 2002 221 226
14. A.D. Gavin, and A.D. Struthers Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure Heart 91 2005 749 753
15. L. Wei, T. Fahey, A.D. Struthers, and T.M. MacDonald Association between allopurinol and mortality in heart failure patients: a long-term follow-up study Int. J. Clin. Pract. 63 2009 1327 1333
16. S.D. Anker, W. Doehner, M. Rauchhaus, R. Sharma, D. Francis, C. Knosalla, C.H. Davos, M. Cicoira, W. Shamim, M. Kemp, R. Segal, K.J. Osterziel, F. Leyva, R. Hetzer, P. Ponikowski, and A.J. Coats Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging Circulation 107 2003 1991 1997
17. E.A. Jankowska, B. Ponikowska, J. Majda, and et al. Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure Int. J. Cardiol. 115 2007 151 155
18. D.A. Pascual-Figal, J.A. Hurtado-Martínez, B. Redondo, and et al. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients Eur. J. Heart Fail. 9 2007 518 524
19. A.L. Alimonda, J. Núñez, E. Núñez, and et al. Hyperuricemia in acute heart failure. More than a simple spectator? Eur. J. Intern. Med. 20 2009 74 79
20. H. Kim, H.W. Shin, J. Son, H.J. Yoon, H.S. Park, Y.K. Cho, C.D. Han, C.W. Nam, S.H. Hur, Y.N. Kim, and K.B. Kim Uric acid as prognostic marker in advanced nonischemic dilated cardiomyopathy: comparison with N-terminal pro B-type natriuretic peptide level Congest. Heart Fail. 16 2010 153 158
21. G. Thanassoulis, J.M. Brophy, H. Richard, and L. Pilote Gout, allopurinol use, and heart failure outcomes Arch. Intern. Med. 170 2010 1358 1364
22. L. Tamariz, A. Harzand, A. Palacio, S. Verma, J. Jones, and J. Hare Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis Congest. Heart Fail. 17 2011 25 30
23. W.C. Levy, D. Mozaffarian, D.T. Linker, and et al. The Seattle Heart Failure Model: prediction of survival in heart failure Circulation 113 2006 1424 1433
24. L. Manzano, D. Babalis, M. Roughton, M. Shibata, S.D. Anker, S. Ghio, D.J. van Veldhuisen, A. Cohen-Solal, A.J. Coats, P.P. Poole-Wilson, M.D. Flather, and SENIORS Investigators Predictors of clinical outcomes in elderly patients with heart failure Eur. J. Heart Fail. 13 2011 528 536
25. M.S. Fragala, A.R. Jajtner, K.S. Beyer, J.R. Townsend, N.S. Emerson, T.C. Scanlon, L.P. Oliveira, J.R. Hoffman, and J.R. Stout Biomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults J. Cachex. Sarcopenia Muscle 5 2014 139 148
26. J.M. Hare, B. Mangal, J. Brown, and et al. OPT-CHF investigators. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study J. Am. Coll. Cardiol. 51 2008 2301 2309
27. M.M. Givertz, D.L. Mann, K.L. Lee, J.C. Ibarra, E.J. Velazquez, A.F. Hernandez, A.M. Mascette, and E. Braunwald Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study Circ. Heart Fail. 6 2013 862 868
28. J.M. McCord, and I. Fridovich The reduction of cytochrome c by milk xanthine oxidase J. Biol. Chem. 243 1968 5753 5760
29. E. Tubaro, B. Lotti, G. Cavallo, C. Croce, and G. Borelli Liver xanthine oxidase increase in mice in three pathological models. A possible defence mechanism Biochem. Pharmacol. 29 1980 1939 1943
30. I.C. Scott, W. Tomlinson, A. Walding, B. Isherwood, and I.G. Dougall Large-scale isolation of human skeletal muscle satellite cells from post-mortem tissue and development of quantitative assays to evaluate modulators of myogenesis J. Cachex. Sarcopenia Muscle 4 2013 157 169
31. A.J. Maxwell, and K.A. Bruinsma Uric acid is closely linked to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease J. Am. Coll. Cardiol. 38 2001 1850 1858
32. M. Ashraf, and Z.Q. Samra Subcellular distribution of xanthine oxidase during cardiac ischemia and reperfusion: an immunocytochemical study J. Submicrosc. Cytol. Pathol. 25 1993 193 201
33. W. Doehner, S. von Haehling, and S.D. Anker Uric acid as a prognostic marker in acute heart failure - new expectations from an old molecule Eur. J. Heart Fail. 9 2007 437 439
34. Z.A. Bakhtiiarov Changes in xanthine oxidase activity in patients with circulatory failure Ter. Arkh. 61 1989 68 69 (Article in Russian)
35. U. Landmesser, S. Spiekermann, S. Dikalov, H. Tatge, R. Wilke, C. Kohler, D.G. Harrison, B. Hornig, and H. Drexler Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase Circulation 106 2002 3073 3078
36. W. Doehner, M.T. Tarpey, D.V. Pavitt, A.P. Bolger, R. Wensel, S. von Haehling, D.A. Reaveley, and S.D. Anker Elevated plasma xanthine oxidase activity in chronic heart failure: source of increased oxygen radical load and effect of allopurinol in a placebo controlled, double blinded treatment study J. Am. Coll. Cardiol. 42 Suppl. 207A 2003
37. K. Josiak, E.A. Jankowska, M.F. Piepoli, W. Banasiak, and P. Ponikowski Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones J. Cachex. Sarcopenia Muscle 5 2014 287 296
38. S. Fülster, M. Tacke, A. Sandek, N. Ebner, C. Tschöpe, W. Doehner, S.D. Anker, and S. von Haehling Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF) Eur. Heart J. 34 2013 512 519
39. J.E. Morley, S.D. Anker, and S. von Haehling Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology - update 2014 J. Cachex. Sarcopenia Muscle 5 2014 253 259
40. S. von Haehling, and S.D. Anker Prevalence, incidence and clinical impact of cachexia: facts and numbers - update 2014 J. Cachex. Sarcopenia Muscle 5 2014 261 263
41. W. Doehner, M. Rauchhaus, P. Ponikowski, I.F. Godsland, S. von Haehling, D.O. Okonko, F. Leyva, A.J. Proudler, A.J. Coats, and S.D. Anker Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure J. Am. Coll. Cardiol. 46 2005 1019 1026
42. Steinbeck L. von Haehling, W. Doehner, J. Springer, and S.D. Anker Muscle wasting in heart failure: an overview Int. J. Biochem. Cell Biol. 45 2013 2257 2265
43. J.E. Morley, S. von Haehling, S.D. Anker, and B. Vellas From sarcopenia to frailty: a road less traveled J. Cachex. Sarcopenia Muscle 5 2014 5 8
44. W. Doehner, and U. Landmesser Xanthine oxidaseand uric acid in cardiovascular disease: clinical impact and therapeutic options Semin. Nephrol. 31 2011 433 440
45. U. Landmesser, S. Spiekermann, C. Preuss, S. Sorrentino, D. Fischer, C. Manes, M. Mueller, and H. Drexler Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease Arterioscler. Thromb. Vasc. Biol. 27 2007 943 948
46. S. Baldus, R. Koster, P. Chumley, T. Heitzer, V. Rudolph, M.A. Ostad, A. Warnholtz, H.J. Staude, F. Thuneke, K. Koss, J. Berger, T. Meinertz, B.A. Freeman, and T. Munzel Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease Free Radic. Biol. Med. 39 2005 1184 1190
47. W. Doehner, N. Schoene, M. Rauchhaus, F. Leyva-Leon, D.V. Pavitt, D.A. Reaveley, G. Schuler, A.J. Coats, S.D. Anker, and R. Hambrecht Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies Circulation 105 2002 2619 2624
48. S. von Haehling, S.M. Bode-Böger, J. Martens-Lobenhoffer, M. Rauchhaus, J.C. Schefold, S. Genth-Zotz, T. Karhausen, M. Cicoira, S.D. Anker, and W. Doehner Elevated levels of asymmetric dimethylarginine in chronic heart failure: a pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol Clin. Pharmacol. Ther. 88 2010 506 512
49. T. Ukai, C.P. Cheng, H. Tachibana, A. Igawa, Z.S. Zhang, H.J. Cheng, and W.C. Little Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure Circulation 103 2001 750 755
50. J. Springer, A. Tschirner, K. Hartman, S. Palus, E.K. Wirth, S.B. Ruis, N. Möller, S. von Haehling, J.M. Argiles, J. Köhrle, V. Adams, S.D. Anker, and W. Doehner Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia Int. J. Cancer 131 2012 2187 2196
51. J. Springer, A. Tschirner, K. Hartman, S. von Haehling, S.D. Anker, and W. Doehner The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy Int. J. Cardiol. 168 2013 3527 3531
52. S. Palus, S. von Haehling, and J. Springer Muscle wasting: an overview of recent developments in basic research J. Cachex. Sarcopenia Muscle 5 2014 193 198
53. M.S. Pötsch, A. Tschirner, S. Palus, S. von Haehling, W. Doehner, J. Beadle, A.J. Coats, S.D. Anker, and J. Springer The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats J. Cachex. Sarcopenia Muscle 5 2014 149 158
54. C. Pietra, Y. Takeda, N. Tazawa-Ogata, M. Minami, X. Yuanfeng, E.M. Duus, and R. Northrup Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile J. Cachex. Sarcopenia Muscle 5 2014 329 337
55. J.C. Peter, H. Rossez, M. Weckering, G. Zipfel, A.C. Lecourt, J.B. Owen, W.A. Banks, and K.G. Hofbauer Protective effects of an anti-melanocortin-4 receptor scFv derivative in lipopolysaccharide-induced cachexia in rats J. Cachex. Sarcopenia Muscle 4 2013 79 88
56. J.E. Morley, S. von Haehling, and S.D. Anker Are we closer to having drugs to treat muscle wasting disease? J. Cachex. Sarcopenia Muscle 5 2014 83 87
57. N. Ebner, L. Steinbeck, W. Doehner, S.D. Anker, and S. von Haehling Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies J. Cachex. Sarcopenia Muscle 5 2014 27 34
58. P.L. de Campos-Ferraz, I. Andrade, W. das Neves, I. Hangai, C.R. Alves, and A.H. Lancha Jr. An overview of amines as nutritional supplements to counteract cancer cachexia J. Cachex. Sarcopenia Muscle 5 2014 105 110
59. A. Omlin, D. Blum, J. Wierecky, S.R. Haile, F.D. Ottery, and F. Strasser Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case-control study J. Cachex. Sarcopenia Muscle 4 2013 55 61
60. H. Wakabayashi, and K. Sakuma Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management J. Cachex. Sarcopenia Muscle 5 2014 269 277
61. C.M. Rhee, and K. Kalantar-Zadeh Resistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients? J. Cachex. Sarcopenia Muscle 5 2014 177 180
62. D.L. Kirkman, P. Mullins, N.A. Junglee, M. Kumwenda, M.M. Jibani, and J.H. Macdonald Anabolic exercise in haemodialysis patients: a randomised controlled pilot study J. Cachex. Sarcopenia Muscle 5 2014 199 207
63. W. Doehner, S. von Haehling, and S.D. Anker Uric acid in CHF: marker or player in a metabolic disease? Int. J. Cardiol. 115 2007 156 158
64. K. Ogino, M. Kato, Y. Furuse, Y. Kinugasa, K. Ishida, S. Shuichi Osaki, T. Kinugawa, O. Igawa, I. Hisatome, C. Shigemasa, S.D. Anker, and W. Doehner Uric acid lowering treatment with benzbromarone in patients with heart failure: a double blind placebo-controlled cross-over preliminary study Circ. Heart Fail. 3 2010 73 81
65. J. George, E. Carr, J. Davies, J.J. Belch, and A. Struthers High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid Circulation 114 2006 2508 2516
66. W.S. Waring, J.A. McKnight, D.J. Webb, and S.R. Maxwell Lowering serum urate does not improve endothelial function in patients with type 2 diabetes Diabetologia 50 2007 2572 2579
67. W. Doehner, and S.D. Anker Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure? Heart 91 2005 707 709
68. J.M. Argilés, C.C. Fontes-Oliveira, M. Toledo, F.J. López-Soriano, and S. Busquets Cachexia: a problem of energetic inefficiency J. Cachex. Sarcopenia Muscle 5 2014 279 286
69. A. Noman, D.S. Ang, S. Ogston, C.C. Lang, and A.D. Struthers Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial Lancet 375 2010 2161 2167
70. M.A. Becker, H.R. Schumacher Jr., R.L. Wortmann, P.A. MacDonald, D. Eustace, W.A. Palo, J. Streit, and N. Joseph-Ridge Febuxostat compared with allopurinol in patients with hyperuricemia and gout N. Engl. J. Med. 353 2005 2450 2461
71. P. Ye, S. Yang, W. Zhang, Q. Lv, Q. Cheng, M. Mei, T. Luo, L. Liu, S. Chen, and Q. Li Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis Clin. Ther. 35 2013 180 189
72. N.L. Edwards Febuxostat: a new treatment for hyperuricaemia in gout Rheumatology (Oxford) 48 Suppl. 2 2009 ii15 ii19
73. D. Grassi, R. Pontremoli, R. Bocale, C. Ferri, and G. Desideri Therapeutic approaches to chronic hyperuricemia and gout High Blood Press. Cardiovasc. Prev. 21 2014 243 250
74. T.M. MacDonald, I. Ford, G. Nuki, I.S. Mackenzie, R. De Caterina, E. Findlay, J. Hallas, C.J. Hawkey, S. Ralston, M. Walters, J. Webster, J. McMurray, F. Perez Ruiz, and C.G. Jennings Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia BMJ Open 4 2014 e005354
75. E.C. Hinch, M.J. Sullivan-Gunn, V.C. Vaughan, M.A. McGlynn, and P.A. Lewandowski Disruption of pro-oxidant and antioxidant systems with elevated expression of the ubiquitin proteosome system in the cachectic heart muscle of nude mice J. Cachex. Sarcopenia Muscle 4 2013 287 293
76. M. Konishi, L. Pelgrim, A. Tschirner, A. Baumgarten, S. von Haehling, S. Palus, W. Doehner, S.D. Anker, and J. Springer Febuxostat improves outcome in a rat model of cancer cachexia J. Cachex. Sarcopenia Muscle 6 2015 174 180